Suggested remit: To evaluate the benefits and costs of palovarotene within its marketing authorisation for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva for national commissioning by NHS England.
Status Awaiting development
Decision None selected
Process HST
ID number 3739

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
14 March 2022 (14:00) Scoping workshop
18 January 2022 - 15 February 2022 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual